Case Studies

Sensors & Wearables
Breast Cancer

Signant's customer conducted a breast cancer study focusing on the impact of treatment on patients' daily lives, using Signant's ePRO app and Actigraph wearable sensors for remote data collection.

Central Ratings
MDD

Signant's central raters evaluated site-based MADRS ratings in MDD trials by comparing them with independent audio scores to ensure reliability and provide feedback for consistent and accurate scoring.

COVID-19

Signant efficiently deployed electronic diaries via its eCOA solution, distributing 38,000 devices across 7 countries amidst pandemic-induced logistical challenges, enabling secure data management & facilitating rapid interim analyses.

Oncology

Signant helped a top pharmaceutical company prove the efficacy and safety of a novel oncology treatment. The treatment was awarded FDA approval in spring 2021 and EMA approval in winter 2022.

Psoriatic Arthritis

Signant leveraged its scale management and digital health science expertise to acquire and implement a proprietary scoring algorithm required to measure safety and efficacy in a psoriatic arthritis (PsA) trial.

CNS - Narcolepsy Type 1

Signant stepped in to aid an organization's clinical programs in three Phase II narcolepsy type 1 studies, using a consultative approach and expertise to overcome delays, highlighting the need for more than just technological solutions.

COVID-19 - Shionogi - Japan

Alzheimer's Disease

In response to COVID-19 movement restrictions, a multinational Alzheimer's disease study prompted a global pharmaceutical company to adopt remote clinical ratings, incorporating telemedicine, video ratings, and scientific expertise.

Vaccine - Mega Trial

Our adaptable eCOA solution facilitated seamless collaboration with a reimbursement provider, effectively boosting engagement throughout the extensive follow-up period of the largest vaccine trial to date, involving over 44,000 subjects across more than 150 sites.

Remote Sample Collection 
Infectious Disease

CNS-Psychiatry

A top Japanese pharmaceutical company selected Signant Health's eConsent solution, following vendor testing, for their first eConsent implementation. It offered the flexibility needed for advanced document management in pediatric trials, accommodating multiple consent forms and language requirements.

Tardive Dyskinesia

For a successful outcome in a pivotal efficacy trial, a global pharmaceutical company focused on consistently measuring the primary endpoint: clinician ratings of abnormal, involuntary movements in tardive dyskinesia (TD) patients, optimizing signal detection in this critical movement disorder study.

Immunology

Global Specialty Biotech

A Japan-based pharmaceutical and biotechnology company improved efficiency by centralizing and digitizing inventory management with Signant's GxP Inventory solution, consolidating supply operations and reducing risks across the clinical supply chain.

Biopharmaceutical

A U.S.-based clinical research sponsor upgraded from manual, decentralized inventory management to Signant SmartSignals GxP Inventory, achieving enhanced supply chain visibility, cost reduction, risk mitigation, and increased efficiency.

Top 20 Pharma

CNS - Substance Use

A Japan-based pharmaceutical development company collaborated with Signant Health for endpoint quality solutions in phase 3 and long-term extension trials for substance use disorder treatment. Signant's technology and expertise optimized endpoint reliability across multiple sites amidst complexities in clinical outcome assessments and rating instruments.

Oncology | Multiple Myeloma

Signant Biotech aided an emerging biopharmaceutical company in expediting phase I of a new relapsed/refractory multiple myeloma treatment, leading to a successful application for breakthrough therapy designation.

Infectious Disease

CNS - Rescue Study

Signant Biotech helped an emerging biopharmaceutical company get an ongoing phase III study back on track after addressing concerns with an existing vendor. They migrated the study smoothly with minimal site disruption, implemented amendments promptly, and delivered an integrated EDC and RTSM solution for a second study on schedule.

Oncology | Multiple Myeloma

Signant Biotech aided an emerging biopharmaceutical company in expediting phase I of a new relapsed/refractory multiple myeloma treatment, leading to a successful application for breakthrough therapy designation.